Clinical Trials Logo
  1. Home
  2. Immunoglobulin A Nephropathy
  3. NCT05162066

BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW)

Membranous Nephropathy Clinical Trial

Official title:
An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With C3G, IgAN, or PMN

Clinical Trial Summary

The purpose of this study is to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

Clinical Trial Description

This is an open-label, multicenter, proof-of-concept study to evaluate the safety, tolerability, and therapeutic potential of BCX9930 administered for 52 weeks in adult (≥ 18 years old) participants with either C3G, IgAN, or PMN. All participants will be enrolled into one of the three parallel treatment cohorts based on diagnosis of C3G, IgAN, or PMN and will receive BCX9930 for the 52-week treatment period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05162066
Study type Interventional
Source BioCryst Pharmaceuticals
Contact
Status Terminated
Phase Phase 2
Start date October 29, 2021
Completion date September 23, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04095156 - Autoreactive B Cells in Membranous Nephropathy
Not yet recruiting NCT06341205 - Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) Phase 3
Active, not recruiting NCT04893096 - MOR202 for Refractory MN Phase 2
Completed NCT00405340 - Rituximab in the Treatment of Idiopathic Membranous Nephropathy Phase 0
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Active, not recruiting NCT04652570 - Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy Phase 1/Phase 2
Recruiting NCT03929887 - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Active, not recruiting NCT03949855 - Belimumab With Rituximab for Primary Membranous Nephropathy Phase 2
Not yet recruiting NCT06242327 - An Outcome Analysis of Primary Membranous Nephropathy
Completed NCT00983034 - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy N/A
Completed NCT03025828 - Adrenocorticotropic Hormone in Membranous Nephropathy Phase 4
Recruiting NCT05732402 - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases Phase 1/Phase 2
Enrolling by invitation NCT04571658 - NEPTUNE Match Study
Recruiting NCT05894512 - Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
Not yet recruiting NCT05941845 - Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy Phase 2
Completed NCT00518219 - To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) Phase 4
Completed NCT02199145 - Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy N/A
Not yet recruiting NCT04326218 - Immunopathological Analysis in a French National Cohort of Membranous Nephropathy N/A
Active, not recruiting NCT03453619 - Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Phase 2
Completed NCT01955187 - Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy Phase 3